{
    "nct_id": "NCT04677816",
    "official_title": "Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients Receiving Neoadjuvant Chemotherapy for Operable Triple Negative Breast Cancer",
    "inclusion_criteria": "* Women or men with histologically confirmed invasive mammary carcinoma.\n* Known triple negative ER/PR/HER2 receptor status as defined by:\n\n  * ER and PR less than or equal to 10% and\n  * HER2 negative based on one of the following:\n  * IHC 0 or 1+\n  * IHC 2+ and FISH negative\n  * IHC 2+ and FISH equivocal and no indication for HER2 targeted therapy based on the treating investigators discretion (i.e., HER2: CEP17 ratio < 2.0 or HER2 total copy number <6)\n* Patients who are scheduled to undergo definitive surgical treatment with lumpectomy or mastectomy with axillary lymph node staging after neoadjuvant chemotherapy.\n* ECOG performance status of 0, 1 or 2.\n* Age â‰¥ 18.\n* The effects of high dose vitamin D on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n* Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative).\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with nephrolithiasis within the past year.\n* Patients with known sarcoidosis.\n* Patients with corrected calcium >10.5 mg/dL within 30 days prior to initiation of chemotherapy.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to vitamin D.\n* Pregnant women are excluded from this study because vitamin D supplementation greater than the recommended daily allowance (RDA) is a pregnancy class C agent with no adequate or well controlled studies in humans.\n* Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with high dose vitamin D (greater than RDA), women who are breastfeeding are excluded from this study.\n* Prior treatment for this malignancy including surgery, radiation therapy, chemotherapy, hormonal therapy or investigational agent prior to study entry.\n* Patients currently taking Vitamin D at a dose of 50,000 International Units (IU) once weekly.",
    "miscellaneous_criteria": ""
}